Translating base editors: a decade of progress from the bench to the clinic

Base editing, pioneered with cytosine editors in 2016, has evolved rapidly into a precise gene-editing technology now used in clinical trials for diseases like sickle cell and metabolic disorders. This progress marks a shift from disruptive gene editing to highly targeted DNA correction with growing adoption in human therapeutics.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.